Skip to main navigation Skip to search Skip to main content

Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy

  • Benjamin D. Horne
  • , Petra A. Lenzini
  • , Mia Wadelius
  • , Andrea L. Jorgensen
  • , Stephen E. Kimmel
  • , Paul M. Ridker
  • , Niclas Eriksson
  • , Jeffrey L. Anderson
  • , Munir Pirmohamed
  • , Nita A. Limdi
  • , Robert C. Pendleton
  • , Gwendolyn A. Mcmillin
  • , James K. Burmester
  • , Daniel Kurnik
  • , C. Michael Stein
  • , Michael D. Caldwell
  • , Charles S. Eby
  • , Anders Rane
  • , Jonatan D. Lindh
  • , Jae Gook Shin
  • Ho Sook Kim, Pantep Angchaisuksiri, Robert J. Glynn, Kathryn E. Kronquist, John F. Carlquist, Gloria R. Grice, Robert L. Barrack, Juan Li, Brian F. Gage

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)232-240
Number of pages9
JournalThrombosis and Haemostasis
Volume107
Issue number2
DOIs
StatePublished - 2012

ASJC Scopus Subject Areas

  • Hematology

Keywords

  • CYP2C9
  • Pharmacogenetic
  • VKORC1
  • Warfarin

Cite this